




RealRate

PHARMACEUTICAL 2017

Corcept Therapeutics INC
Rank 111 of 308



The relative strengths and weaknesses of Corcept Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corcept Therapeutics INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Corcept Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 306%, being 61% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	65,689
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,374
Liabilities, Non-Current	0
Other Assets	2,859
Other Compr. Net Income	0
Other Expenses	4,097
Other Liabilities	0
Other Net Income	0
Other Revenues	81,321
Property and Equipment	205
Research and Development	23,844
Selling, General and Administrative Expense	45,240

Output Variable	Value in 1000 USD
Assets	68,753
Liabilities	27,374
Expenses	73,181
Revenues	81,321
Stockholders Equity	41,379
Net Income	8,140
Comprehensive Net Income	8,140
BaseVar	125,314
ECR before LimitedLiability	205%
Economic Capital Ratio	306%